# Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion

- Link: https://www.thailand-business-news.com/pr-news/sino-biopharmaceutical-limited-unveils-new-global-brand-sbp-group-to-accelerate-international-expansion
- Published: 2026-08-19T18:45:00+07:00
- Author: PR Newswire

|   |

HONG KONG, Aug. 19, 2026 /PRNewswire/ — Sino Biopharmaceutical Limited (HKEX: 01177),
a leading innovation-driven pharmaceutical company in China, announced the launch
of its new global brand, SBP Group, during its interim results meeting. SBP stands
for Science, Breakthroughs and Patients: Science is where the company starts; breakthroughs
are what it pursues; patients are why it does what it does. This philosophy aligns
with the Company’s mission, "Science for a Healthier World."

The unified identity reflects the Company’s strategic evolution from a leading domestic
biopharmaceutical company into a global innovator. This transformation is advancing
on two fronts: product globalization, by building a global pipeline of innovative
assets through in-house R&D and acquisition; and business globalization, through
global partnerships and direct commercial expansion in key international markets.
Supported by continued investment in global talent, organizational capabilities 
and infrastructure, the Company aims to bring innovative medicines to more patients
worldwide.  

"2026 marks the first year of executing our globalization strategy, and we have 
made strong progress," said Ms. Theresa Tse, Chairwoman of the Board. "SBP Group
is committed to working with global partners to accelerate the global development
and availability of innovative medicines from China and bring cutting-edge therapies
from around the world to China. Leveraging our AI-driven, fully integrated R&D platform,
we aim to advance breakthroughs at the frontiers of science, with the ultimate goal
of benefiting more patients and improving human health."

To date, the Company has completed four out-licensing transactions with MNCs, with
aggregate upfront payments exceeding US$1 billion and a total potential deal value
of more than US$7 billion, alongside over 30 M&A, licensing and strategic partnership
transaction. 2026 key transactions include (i) the exclusive licensing to Sanofi
of rovadicitinib, a first-in-class dual JAK/ROCK inhibitor, in a transaction valued
at up to US$1.53 billion; and (ii) the exclusive licensing to AstraZeneca of TQC3721,
an inhaled PDE3/4 inhibitor for COPD, in a transaction valued at up to US$1.9 billion.

About SBP Group

Sino Biopharmaceutical Limited (HKEX: 01177), referred to herein as "SBP Group",
is a leading innovation-driven pharmaceutical company in China. The Company has 
end-to-end capabilities across full value chain, including R&D, manufacturing and
commercialization. Its product portfolio covers a wide range of biologics and small
molecule drugs, with a strong leadership position across four core therapeutic areas:
oncology, liver/cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/
analgesia.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion ](http://www.prnasia.com/story/archive/5029441_AE29441_0?rand=184833)